Abstract

Drawing upon an exemplary case surrounding a patent on the anti-cancer drug Gleevec, I trace how intellectual property regimes drive the re-institutionalization of pharmaceutical development in India today in unsettled and contested ways. I am interested in how this case resolves, in an apparent purification, into technical and constitutional components; how the technical components are entirely unsettled; and how the constitutional components open up questions regarding the relationship between biocapital and issues of constitutionalism, rights, and corporate social responsibility